Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing innovative therapies for eye diseases and conditions using its proprietary bioresorbable hydrogel-based formulation technology, ELUTYX™. The company has successfully commercialized its product, DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery, and for ocular itching associated with allergic conjunctivitis. With a robust product pipeline, Ocular Therapeutix aims to streamline current standards of care and establish itself as a leader in the ophthalmic space. The lead clinical program, AXPAXLI™, is being developed to address wet AMD and diabetic retinopathy. The company also has other promising clinical programs such as PAXTRAVA™, OTX-CSI, and OTX-DED for various eye conditions.

Founded in 2006 and headquartered in the United States, Ocular Therapeutix recently secured a $325.00M Post-IPO Equity investment on 22 February 2024. This investment round saw participation from influential investors including Acuta Capital, Deep Track Capital, Logos Capital, Perceptive Advisors, TCG Crossover, Great Point Partners, Venrock Healthcare Capital Partners, Opaleye Management, and Surveyor Capital.